AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors (Q64662311)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors |
clinical trial |
Statements
A CCLG/Cancer Research UK Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) Given for 72 Hours Every 21 Days Via Intravenous Infusion in Children and Adolescents With Relapsed and Refractory Solid Tumors (English)
0 references
September 2009
0 references
25 January 2016
0 references
33
0 references
2 year
0 references
18 year
0 references